The US Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for Astellas and Pfizer’s Xtandi (enzalutamide), the companies have announced.

The filing is to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), and has also been granted Priority Review, a designation given to those applications for drugs that, if approved, may offer significant improvements in the safety or effectiveness of the treatment, diagnosis or

A new report in the British Journal of General Practice has revealed that children prescribed more than two courses of antibiotics within a year for coughs, sore throat and earache are less likely to respond to a subsequent course.

The cohort study, compiled of statistics from the Clinical Practice Research Datalink, identified UK primary care data for children aged one to five years during the period 2009 to 2016, excluding children requiring long-term antibiotic treatment for chronic respiratory diseases such as TB. The analysed data showed that for the 114,329 children who were prescribed

The Health Service Executive (HSE) has granted reimbursement for Pierre Fabre’s Braftovi (encorafenib) and Mektovi (binimetinib) combination in Ireland.

The treatment has been accepted for use on the Irish health service to treat adult patients with unresectable or metastatic melanoma with a mutation in the BRAF V600 gene. The reimbursement means that eligible patients in the Republic of Ireland can potentially benefit from the combination with immediate effect, and